Scinai Immunotherapeutics Statistics
Total Valuation
SCNI has a market cap or net worth of $1.78 million. The enterprise value is $2.39 million.
Important Dates
The last earnings date was Wednesday, April 1, 2026, before market open.
| Earnings Date | Apr 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SCNI has 3.96 million shares outstanding. The number of shares has increased by 189.55% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 3.96M |
| Shares Change (YoY) | +189.55% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 10.51% |
| Owned by Institutions (%) | 3.19% |
| Float | 3.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.36 |
| Forward PS | n/a |
| PB Ratio | 0.63 |
| P/TBV Ratio | 0.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.30, with a Debt / Equity ratio of 0.28.
| Current Ratio | 1.30 |
| Quick Ratio | 1.15 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -21.01 |
Financial Efficiency
Return on equity (ROE) is -91.89% and return on invested capital (ROIC) is -42.03%.
| Return on Equity (ROE) | -91.89% |
| Return on Assets (ROA) | -37.60% |
| Return on Invested Capital (ROIC) | -42.03% |
| Return on Capital Employed (ROCE) | -75.11% |
| Weighted Average Cost of Capital (WACC) | 14.17% |
| Revenue Per Employee | $29,133 |
| Profits Per Employee | -$184,600 |
| Employee Count | 45 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.52% in the last 52 weeks. The beta is 2.19, so SCNI's price volatility has been higher than the market average.
| Beta (5Y) | 2.19 |
| 52-Week Price Change | -83.52% |
| 50-Day Moving Average | 0.58 |
| 200-Day Moving Average | 0.99 |
| Relative Strength Index (RSI) | 39.46 |
| Average Volume (20 Days) | 211,856 |
Short Selling Information
The latest short interest is 157,814, so 4.01% of the outstanding shares have been sold short.
| Short Interest | 157,814 |
| Short Previous Month | 642,343 |
| Short % of Shares Out | 4.01% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, SCNI had revenue of $1.31 million and -$8.31 million in losses. Loss per share was -$3.56.
| Revenue | 1.31M |
| Gross Profit | -2.65M |
| Operating Income | -7.54M |
| Pretax Income | -8.31M |
| Net Income | -8.31M |
| EBITDA | -6.12M |
| EBIT | -7.54M |
| Loss Per Share | -$3.56 |
Full Income StatementBalance Sheet
The company has $1.66 million in cash and $2.27 million in debt, with a net cash position of -$606,000 or -$0.15 per share.
| Cash & Cash Equivalents | 1.66M |
| Total Debt | 2.27M |
| Net Cash | -606,000 |
| Net Cash Per Share | -$0.15 |
| Equity (Book Value) | 8.10M |
| Book Value Per Share | 0.71 |
| Working Capital | 469,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.03 million and capital expenditures -$24,000, giving a free cash flow of -$6.06 million.
| Operating Cash Flow | -6.03M |
| Capital Expenditures | -24,000 |
| Depreciation & Amortization | 1.42M |
| Net Borrowing | n/a |
| Free Cash Flow | -6.06M |
| FCF Per Share | -$1.53 |
Full Cash Flow StatementMargins
| Gross Margin | -202.29% |
| Operating Margin | -575.29% |
| Pretax Margin | -633.64% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SCNI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -189.55% |
| Shareholder Yield | -189.55% |
| Earnings Yield | -466.19% |
| FCF Yield | -339.80% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 21, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | May 21, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
SCNI has an Altman Z-Score of -16.64 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -16.64 |
| Piotroski F-Score | 2 |
